Support cells in the brain secretly help glioblastoma grow — and blocking their signals slows tumors dramatically
Glioblastoma (GBM) is one of the most lethal cancers, in part because it co-opts its surrounding environment to support its own growth. A Canadian research team found that certain brain cells — previously thought to only support healthy neurons — can actually promote glioblastoma growth by sending…
Support cells in the brain secretly help glioblastoma grow — and blocking their signals slows tumors dramatically
Glioblastoma (GBM) is one of the most lethal cancers, in part because it co-opts its surrounding environment to support its own growth. A Canadian research team found that certain brain cells — previously thought to only support healthy neurons — can actually promote glioblastoma growth by sending chemical signals that strengthen cancer cells.
When researchers blocked this intercellular communication pathway in lab models, tumor growth slowed dramatically. This identifies a previously unknown vulnerability: targeting the tumor-supporting signaling from these brain cells, rather than (or in addition to) the cancer cells directly.
The specific cell type and signaling molecules involved are described as 'brain support cells' (likely astrocytes or microglia, though not specified in the summary), which are abundant in glioblastoma's tumor microenvironment.
Key Findings
- Certain non-cancerous brain support cells promote glioblastoma growth through paracrine signaling
- Blocking this intercellular communication significantly slowed tumor growth in lab models
- These support cells were previously considered benign bystanders in tumor biology
- Finding reveals a new therapeutic vulnerability in glioblastoma's tumor microenvironment
- Research conducted by Canadian team (specific institution not specified)
Implications
Targeting the supportive crosstalk between brain cells and GBM could be a novel therapeutic approach, potentially complementing standard GBM treatments. This is particularly valuable since GBM is so resistant to current therapies, and targeting the microenvironment rather than just the tumor cells themselves offers a new angle.
Caveats
Based on brief news summary; specific cell types, signaling pathways, and lab model details not available. 'Lab models' could mean cell lines or animal models — in vivo validation in animal models and then humans needed. Summary based on abstract only.
Source: ScienceDaily Cancer — 2026-04-05
